Why Grail Stock Soared Nearly 70% in One Week. And what to watch next.

Grail (GRAL) stock soared in September, hitting a record high, as the Food and Drug Administration mulls its Galleri blood test, a competitor in the multibillion-dollar cancer detection market. Earlier this month, an FDA advisory committee supported Galleri’s safety and effectiveness, saying the benefits outweigh the risks. Today, Galleri is on the verge of full approval. However…